“We are trying to maintain patient programs, but we need funding to do it and that is why the walk is so important," said ...

For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...

A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus (SLE) with persistently active disease (PAD). Researchers found that both ...

Two new studies led by researchers at Hospital for Special Surgery (HSS) have uncovered key biological mechanisms driving ...

In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...